PAHC FY26 net income doubles to $99.7M (+107%) on Zoetis MFA integration; Brazil bans virginiamycin for growth promotion

Filed August 26, 2026 · Period ending June 30, 2026 · Compared to 10-K Aug 27, 2025 · ~2 min read

Key Changes

• high

  Net income rose 106.6% to $99.7M (diluted EPS $2.43, +104.2%) as operating income climbed 76% to $194.4M. The Zoetis MFA portfolio contributed $358.2M in its first full year vs. $208.2M in the eight-month stub, lifting total revenue 17.1% to $1.52B.

  MD&A: Financial Results verify on EDGAR →
• high

  Brazil's MAPA banned virginiamycin for growth promotion effective April 2026 (180-day transition). The company is pursuing therapeutic-indication registrations (in final review) to maintain access; virginiamycin sales in Brazil were ~$27M in FY26.

  MD&A: Brazil Regulatory Update verify on EDGAR →
• high

  Management announced closure of the Chicago Heights manufacturing facility (production shutdown summer 2027) as part of plant-network consolidation. Production will shift to other internal sites and third-party contract manufacturers; financial impacts not yet estimable.

  Business: Subsequent Events verify on EDGAR →